{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-075736","form_type":"8-K/A","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2023-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.086562+00:00","generated_at":"2026-06-17T22:19:00.652581+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Enliven Therapeutics files audited FY2022 financials with net loss of $37.7M; pro forma cash from $164.5M financing","bullets":["Net loss of $37.7M for year ended Dec 31, 2022 vs $24.7M in 2021; R&D spend rose 51% to $31.0M.","Cash and equivalents of $75.5M at Dec 31, 2022; $164.5M PIPE closed concurrently with merger on Feb 23, 2023.","Pro forma financials reflect reverse recapitalization with Imara Inc.; Enliven is accounting acquirer.","Accumulated deficit of $82.9M; company expects current cash to fund ops for at least 12 months.","Audited balance sheet shows total assets of $83.3M and total liabilities of $10.4M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-075736","json":"https://secwatch.observer/filing/0001193125-23-075736.json","markdown":"https://secwatch.observer/filing/0001193125-23-075736.md","text":"https://secwatch.observer/filing/0001193125-23-075736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523075736/0001193125-23-075736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523075736/d415677d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:19:00.652581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}